<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02797028</url>
  </required_header>
  <id_info>
    <org_study_id>No. 81402671</org_study_id>
    <nct_id>NCT02797028</nct_id>
  </id_info>
  <brief_title>Investigation of the Atherogenic Effects of Uric Acid-modified in Endothelial Dysfunction and the the Preventional Mechanism by Anthocyanidines</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou General Hospital of Guangzhou Military Command</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guangzhou General Hospital of Guangzhou Military Command</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm the protective effect and mechanism of anthocyanins
      on hyperuricemia patients with Cardiovascular disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hyperuricemia patients who have the ability to complete the intervention study in the early
      stage of study were selected as the research subjects. A randomized controlled double blind
      control method was used to study the effect of one year of anthocyanins intervention. Serum
      UA levels, oxidative stress, AGEs, and endothelial function are detecting in patients with
      hyperuricemia who were treated with anthocyanins and placebo. Providing scientific basis of
      anthocyanins for the treatment with hyperuricemia and delaying atherosclerosis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of serum uric acid levels in all patients</measure>
    <time_frame>up to 1 months</time_frame>
    <description>Serum uric acid (mg/dl) is determined by Uric Acid kit on an automated system.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of advanced glycation end products and its receptor level in all patients</measure>
    <time_frame>up to 2 months</time_frame>
    <description>Advanced glycation end products and its receptor level are determined by high efficiency liquid chromatography.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Placebo capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Simple hyperuricemia patients and with coronary heart disease in hospital. Double blind, randomized method. Control group taking placebo capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anthocyanidins capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simple hyperuricemia patients and with coronary heart disease in hospital. Double blind, randomized method. The experimental group taking anthocyanins capsule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allopurinol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental group taking allopurinol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Anthocyanidins capsule</intervention_name>
    <description>Continuous intervention for 1 years, detect the indicators in the intervention of 0,6,12 months</description>
    <arm_group_label>Anthocyanidins capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo capsule</intervention_name>
    <description>Continuous intervention for 1 years, detect the indicators in the intervention of 0,6,12 months</description>
    <arm_group_label>Placebo capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>Continuous intervention for 1 years, detect the indicators in the intervention of 0,6,12 months</description>
    <arm_group_label>Allopurinol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Serum uric acid &gt;420μmol/L (7mg/dL) in male, &gt;360μmol/L (6mg/dL) in female identified
             as hyperuricemia patients.

        Exclusion Criteria:

          -  Age more than 60 years and less than 30 years old;

          -  acute infection, tumor, recent surgery, need for hemodialysis and autoimmune diseases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hui Dai</last_name>
    <phone>020-36653321</phone>
    <email>daihui66@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuan Zhang</last_name>
    <phone>020-61653566</phone>
    <email>1035834805@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>General Hospital of Guangzhou Military Command of People's Liberation Army</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Dai</last_name>
      <phone>020-36653321</phone>
      <email>daihui66@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Yuan Zhang</last_name>
      <phone>020-61653566</phone>
      <email>1035834805@qq.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004 Jun 15;109(23 Suppl 1):III27-32. Review.</citation>
    <PMID>15198963</PMID>
  </reference>
  <reference>
    <citation>Gimbrone MA Jr. Endothelial dysfunction and atherosclerosis. J Card Surg. 1989 Jun;4(2):180-3. Review.</citation>
    <PMID>2519996</PMID>
  </reference>
  <reference>
    <citation>Verma S, Anderson TJ. Fundamentals of endothelial function for the clinical cardiologist. Circulation. 2002 Feb 5;105(5):546-9. Review.</citation>
    <PMID>11827916</PMID>
  </reference>
  <reference>
    <citation>D'Marco L, García I, Vega C. [Uric acid, atherosclerosis and vascular calcifications in chronic kidney disease]. Invest Clin. 2012 Mar;53(1):52-9. Spanish.</citation>
    <PMID>22524108</PMID>
  </reference>
  <reference>
    <citation>Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008 Oct 23;359(17):1811-21. doi: 10.1056/NEJMra0800885. Review. Erratum in: N Engl J Med. 2010 Jun 10;362(23):2235.</citation>
    <PMID>18946066</PMID>
  </reference>
  <reference>
    <citation>Li C, Han L, Levin AM, Song H, Yan S, Wang Y, Wang Y, Meng D, Lv S, Ji Y, Xu X, Liu X, Wang Y, Zhou L, Miao Z, Mi QS. Multiple single nucleotide polymorphisms in the human urate transporter 1 (hURAT1) gene are associated with hyperuricaemia in Han Chinese. J Med Genet. 2010 Mar;47(3):204-10. doi: 10.1136/jmg.2009.068619. Epub 2009 Oct 14.</citation>
    <PMID>19833602</PMID>
  </reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2016</study_first_submitted>
  <study_first_submitted_qc>June 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2016</study_first_posted>
  <last_update_submitted>June 7, 2016</last_update_submitted>
  <last_update_submitted_qc>June 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou General Hospital of Guangzhou Military Command</investigator_affiliation>
    <investigator_full_name>Yuan Zhang</investigator_full_name>
    <investigator_title>Doctor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Hyperuricemia</keyword>
  <keyword>endothelial function</keyword>
  <keyword>anthocyanidins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
    <mesh_term>Proanthocyanidin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

